EMA to endorse new dose-finding method to cut high Phase III failure rate
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is planning to endorse the use of a new methodology that could improve the way doses of new drugs are selected for use in confirmatory Phase III studies, and hopefully increase the chances of their making it through the final stages of development and onto the market.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.